Compare Kaltura Inc (KLTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kaltura Inc trades at $1.64 (market cap $249.42M), while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| KLTR | XBI | |
|---|---|---|
Market Cap | $249.42M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $1.89 | $164.28 |
52-Week Low | $1.08 | $86.92 |
Enterprise Value | $261.64M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.59, down 3.05% today, with a bullish technical signal from moving averages and strong institutional recognition for its AI-driven digital experience platform. Revenue is stable around $181M annually, but the company remains unprofitable, with a net income margin of -6.92% in 2026. Recent earnings beats and multiple industry awards highlight operational progress amid high valuation multiples like EV/EBITDA of 336.29.
The outlook is cautiously optimistic due to consistent revenue and margin improvements, but persistent losses and high debt pose risks. Analyst sentiment is mixed with a 44.45% buy rating, suggesting potential upside if profitability is achieved, though investor caution is warranted given the negative cash flow and insider selling activity.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
